Skip to main content
.

POWERFUL LDL-C REDUCTION AND LEQVIO® IN THE REAL-WORLD SETTING1,2
 

References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Koren MJ, Rodriguez F, East C, et al. An "inclisiran first" strategy vs usual care in patients with atherosclerotic cardiovascular disease. JACC. 2024;83(20):1939-1952. doi:10.1016/j.jacc.2024.03.382 3. Data on file. ORION-10 Novartis Pharmaceuticals Corp; 2025. 4. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020(supplement):1-31. 5. Data on file. ORION-11 Novartis Pharmaceuticals Corp; 2025. 6. Ray KK, Wright RS, Kallend D, et al; Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. 7. Kumbhani DJ, Cibotti-Sun M, Moore MM. 2025 Acute coronary syndromes guideline-at-a-glance. J Am Coll Cardiol. Published online February 27, 2025. doi:10.1016/j.jacc.2025.01.018 8. Knowlton KU, Navar AM, Anderson JL, et al. LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION. Presented at: National Lipid Association’s 2025 Annual Scientific Sessions; May 29-June 1, 2025; Miami, FL. 9. Data on File. Novartis Pharmaceutical Corp; 2025. 10. Wright RS, Raal FJ, Koenig W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;1-11. doi:10.1093/cvr/cvae109 11. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625